• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Demadex (torsemide) tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – January 2010 and August 2012

 

August 2012

Summary View

 

ADVERSE REACTIONS

Postmarketing Experience
  • Pancreatitis has been reported in association with torsemide use…

 

January 2010 

Summary View

 

ADVERSE REACTIONS

Post-Marketing

  • The following adverse reactions have been identified during the post approval use of the Demadex. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Adverse reactions reported include the following: leukopenia, thrombocytopenia.
  • Serious skin reactions (i.e., Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported in association with torsemide use.